University Of Oxford

4 trials 1 recruiting Academic / non-commercial Merged from 2 name variants

Filter these 4 trials by condition, phase, country and more.

Open in Search →

4 Registered trials

1 Recruiting

2 Completed trials

14 Countries active

15 Unique IMPs

100% Results reported

Phase III

Phase III/IV

Phase IV

Phase III: 2 Phase III/IV: 1 Phase IV: 1

100%

2 of 2 completed trials have published summary results (EU CTR Article 37 — 12-month obligation).

View full Transparency Scoreboard →

Top indications

Monkeypox 1 Schizophreniform disorder 1 Schizophrenia 1 Pneumonia 1

Top IMPs

BALOXAVIR MARBOXIL 1 DEXAMETHASONE PH. EUR. 1 DEXAMETHASONE SODIUM PHOSPHATE 1 HYDROCORTISONE SODIUM SUCCINATE 1 OSELTAMIVIR 1 PREDNISOLONE 1 TECOVIRIMAT 1

All trials

4 total

AugmENtation witH cAnnabidiol iN first episode psyChosis: a doublE blind randomised controlled trial (STEP-ENHANCE Trial) Pending

2025-521929-32-01 Phase III 6 countries
RECOVERY Recruiting

2023-507441-29-00 Phase III 9 countries BALOXAVIR MARBOXIL; DEXAMETHASONE PH. EUR.; DEXAMETHASONE SODIUM PHOSPHATE; HYDR…
Initiation of angiotensin receptor-neprilysin inhibitor (ARNi) and sodium-glucose cotransporter-2 inhibitors (SGLT2i) in patients with heart… Ended

2022-502409-14-00 Phase III/IV 1 country
Cohort study of human mpox virus disease Ended

2022-501132-42-00 Phase IV 8 countries TECOVIRIMAT

Showing 1–4 of 4 trials

← All sponsors A–Z